1 of 2 patent suits filed this year proceed to the 2nd round
By Kim, Jin-Gu | translator Alice Kang
22.12.23 06:20:00
가나다라
0
Novartis files an appeal after generic companies win first trial of patent suits for Entresto
Boryung succeeds in preserving Dukarb patent... companies that lost respond with a two-track strategy
Patent dispute for ‘Galvus’ continues... Novartis counters suit by filing a trial for the ‘active confirmation of the scope of rights'
It seems that the patent disputes in the pharma and bio industry will continue on in the long term. Among the 20 major rulings made during the first trial, 11, over 50% are being retried in a second trial by the Patent Court of Korea.
Both the winning and losing parties of the patent suit that had been filed against Boryung Pharmaceutical’s fixed-dose combination for hypertension, ‘Dukarb (fimasartan and amlodipine),’ opted to continue their dispute in a second trial. In the case of the patent dispute over Novartis’s heart failure treatment ‘Entresto (valsartan+sacubitril),’ the original company appealed after the generic drug companies won the first trial.
In the case of the dispute
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)